BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 1346552)

  • 1. Oncogenes and antioncogenes in human breast carcinoma.
    Leslie KO; Howard P
    Pathol Annu; 1992; 27 Pt 1():321-42. PubMed ID: 1346552
    [No Abstract]   [Full Text] [Related]  

  • 2. Oncogenes and tumour suppressor genes in breast cancer.
    Eccles MR; Phipps RF
    Br J Hosp Med; 1993 Nov 3-16; 50(9):529-36. PubMed ID: 7904528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oncogenes and anti-oncogenes in breast cancer].
    Birnbaum D; Gaudray P
    Bull Cancer; 1989; 76(7):677-87. PubMed ID: 2573395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
    Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
    Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical assessment of tumour behaviour and patient prognosis in human breast cancer.
    Barnes DM
    Dis Markers; 1991; 9(3-4):159-65. PubMed ID: 1687522
    [No Abstract]   [Full Text] [Related]  

  • 6. [Genetic alterations in the genesis and development of ovarian cancer].
    Okamoto A; Yokoyama S; Terashima Y
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1971-6. PubMed ID: 1358031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complex characteristics of the alterations of oncogenes HER-2/ERBB-2, HER-1/ERBB-1, HRAS-1, C-MYC and antioncogenes p53, RB1, as well as deletions of loci of chromosome 17 in colon carcinoma].
    Kniazev PG; Imianitov EN; Chernitsa OI; Nikiforova IF; Babenko VI; Bruderliaĭn S; Plutalo OV; Kuz'min AI; Kaboev OK; Berlin IuA
    Mol Biol (Mosk); 1992; 26(5):1134-47. PubMed ID: 1470178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas.
    Meyers SL; O'Brien MT; Smith T; Dudley JP
    Cancer Res; 1990 Sep; 50(18):5911-8. PubMed ID: 1975511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic proteins and prognostic correlations in breast cancer.
    Molina R; Filelia X; Segui MA; Climent MA; Pérez-Picañol E; Alonso C; Jo J; Ojeda B; Tandon AK; Ballesta AM
    In Vivo; 1993; 7(6B):585-9. PubMed ID: 7910764
    [No Abstract]   [Full Text] [Related]  

  • 10. Proto-oncogene amplification and human breast tumor phenotype.
    Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
    Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene patterns in breast and ovarian carcinomas.
    Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
    Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
    Gaffey MJ; Frierson HF; Williams ME
    Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of oncogenes and tumor suppressor genes in human breast cancer.
    Yamashita H; Kobayashi S; Iwase H; Itoh Y; Kuzushima T; Iwata H; Itoh K; Naito A; Yamashita T; Masaoka A
    Jpn J Cancer Res; 1993 Aug; 84(8):871-8. PubMed ID: 8104920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
    Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in oncogene and antioncogene research].
    Toyoshima K; Akiyama T
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):751-6. PubMed ID: 1351383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alterations of oncogenes in human cancers].
    Tsuda H; Hirohashi S
    Gan To Kagaku Ryoho; 1993 May; 20(7):977-83. PubMed ID: 8098201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors.
    Morrison BW; Leder P
    Oncogene; 1994 Dec; 9(12):3417-26. PubMed ID: 7970700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenes related to head and neck cancer.
    Issing WJ; Wustrow TP; Heppt WJ
    Anticancer Res; 1993; 13(6B):2541-51. PubMed ID: 8135494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
    Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
    Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).
    Lavialle C; Modjtahedi N; Lamonerie T; Frebourg T; Landin RM; Fossar N; Lhomond G; Cassingena R; Brison O
    Anticancer Res; 1989; 9(5):1265-79. PubMed ID: 2686529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.